Rohto Pharmaceutical
Rohto Pharmaceutical Co., Ltd., commonly known as Rohto, is a leading Japanese company headquartered in Osaka, Japan. Established in 1899, Rohto has made significant strides in the pharmaceutical and consumer healthcare industries, with a strong presence in Asia, North America, and Europe. The company is renowned for its innovative eye care products, skin care solutions, and over-the-counter medications, which are distinguished by their quality and effectiveness. With a commitment to research and development, Rohto has achieved notable milestones, including the launch of its popular Rohto Eye Drops and the successful expansion of its skincare line, Hada Labo. As a market leader, Rohto continues to enhance its global footprint, driven by a dedication to improving health and well-being through unique, science-backed formulations.
DitchCarbon Score
How does Rohto Pharmaceutical's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Instruments industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Rohto Pharmaceutical's score of 38 is higher than 76% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Rohto Pharmaceutical's reported carbon emissions
In 2023, Rohto Pharmaceutical reported total carbon emissions of approximately 218 million tonnes CO2e, with 8 million tonnes from Scope 1 and 6 million tonnes from Scope 2 emissions. The majority of their emissions, about 218 million tonnes CO2e, were classified under Scope 3, which typically includes indirect emissions from the supply chain and product use. Over the years, Rohto has made significant strides in reducing its emissions. From 2019 to 2023, Scope 1 emissions decreased from 60 million tonnes to 8 million tonnes, while Scope 2 emissions fell from 58 million tonnes to 6 million tonnes. This reflects a commitment to improving operational efficiency and reducing the carbon footprint of their direct operations. Despite these reductions, Rohto's overall emissions remain substantial, particularly in Scope 3, which accounted for the largest share of their total emissions in 2023. The company has been actively engaging in climate initiatives, as evidenced by their participation in the CDP (Carbon Disclosure Project), where they received a score of "C" in 2023, indicating a moderate level of transparency and action on climate-related issues. Rohto Pharmaceutical's ongoing efforts to address climate change demonstrate their commitment to sustainability and reducing their environmental impact, although further targets and specific reduction initiatives have not been detailed in the available data.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 20,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 0,000,000 |
| Scope 2 | 20,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 0,000,000 |
| Scope 3 | - | - | - | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Rohto Pharmaceutical is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
